Lauren Riker Sells 3,970 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 3,970 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total value of $114,018.40. Following the transaction, the senior vice president now owns 38,075 shares in the company, valued at approximately $1,093,514. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pacira BioSciences Price Performance

PCRX stock opened at $28.13 on Friday. Pacira BioSciences, Inc. has a 1 year low of $25.33 and a 1 year high of $41.65. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.78 and a current ratio of 5.81. The stock’s 50 day moving average price is $28.52 and its 200 day moving average price is $29.82. The firm has a market cap of $1.31 billion, a P/E ratio of 19.67 and a beta of 0.87.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. The company had revenue of $167.12 million during the quarter, compared to analysts’ expectations of $165.43 million. On average, sell-side analysts expect that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP purchased a new position in shares of Pacira BioSciences during the 4th quarter worth $40,488,000. Pacer Advisors Inc. lifted its stake in shares of Pacira BioSciences by 397,487.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company’s stock worth $35,146,000 after purchasing an additional 1,041,417 shares during the period. Archon Capital Management LLC purchased a new position in shares of Pacira BioSciences during the 1st quarter worth $15,677,000. Rubric Capital Management LP purchased a new position in shares of Pacira BioSciences during the 3rd quarter worth $14,102,000. Finally, Frontier Capital Management Co. LLC lifted its stake in shares of Pacira BioSciences by 15.8% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock worth $70,332,000 after purchasing an additional 285,045 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a research report on Wednesday, May 8th. JPMorgan Chase & Co. began coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an “overweight” rating and a $45.00 target price on the stock. TheStreet raised Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Needham & Company LLC decreased their price target on Pacira BioSciences from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, Royal Bank of Canada decreased their price target on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $47.40.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.